1. Home
  2. RCEL vs FATE Comparison

RCEL vs FATE Comparison

Compare RCEL & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$5.07

Market Cap

126.8M

Sector

Health Care

ML Signal

HOLD

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$2.72

Market Cap

125.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCEL
FATE
Founded
N/A
2007
Country
United States
United States
Employees
226
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.8M
125.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
RCEL
FATE
Price
$5.07
$2.72
Analyst Decision
Buy
Buy
Analyst Count
5
6
Target Price
$7.88
$4.10
AVG Volume (30 Days)
358.7K
4.9M
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.88
EPS
N/A
N/A
Revenue
N/A
$6,646,000.00
Revenue This Year
$17.17
N/A
Revenue Next Year
$49.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.22
$0.91
52 Week High
$7.12
$3.23

Technical Indicators

Market Signals
Indicator
RCEL
FATE
Relative Strength Index (RSI) 62.21 53.88
Support Level $3.47 $1.01
Resistance Level $5.32 $2.88
Average True Range (ATR) 0.44 0.29
MACD 0.03 0.00
Stochastic Oscillator 65.56 63.08

Price Performance

Historical Comparison
RCEL
FATE

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: